ERBB2 and breast carcinoma: Concomitant overexpression of hormone receptors (HRs) and HER2 is also common, with HR-positivity occurring in ~60–70% of patients with HER2+  breast cancer, albeit typically at lower expression levels than in the case of HER2-negative disease2,4,6–8.